Announces the filing of a patent application seeking to protect its unique combination of MEAI and SciSparc's Palmitoylethanolamide for the treatment of depression. The company filed a provisional patent application with the United States Patent and Trademark Office as part of its ongoing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat central nervous system disorders. Clearmind Medicine Inc shares C.CMND are trading up one cent at $0.88.
Stocks in play: Clearmind Medicine Inc
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
